Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy - The report reviews pipeline therapeutics for Diabetic Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Peripheral Neuropathy therapeutics and enlists all their major and minor projects - The report assesses Diabetic Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Peripheral Neuropathy Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8 Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9 Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10 Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11 Diabetic Peripheral Neuropathy - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Diabetic Peripheral Neuropathy - Products under Development by Companies 14 Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 15 Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 16 Celgene Corporation 16 Commence Bio, Inc. 17 Nuvo Research Inc. 18 Pfizer Inc. 19 Relief Therapeutics S.A. 20 ViroMed Co., Ltd. 21 Diabetic Peripheral Neuropathy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 atexakin alfa - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 benfotiamine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 BNV-222 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CBX-129801 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CMB-200 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drug for Pain - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Flexicaine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ketoprofen - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 PDA-002 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PF-05089771 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 VM-202 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Diabetic Peripheral Neuropathy - Recent Pipeline Updates 48 Diabetic Peripheral Neuropathy - Dormant Projects 52 Diabetic Peripheral Neuropathy - Discontinued Products 53 Diabetic Peripheral Neuropathy - Product Development Milestones 54 Featured News & Press Releases 54 Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 54 Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2016 8 Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Diabetic Peripheral Neuropathy - Pipeline by Celgene Corporation, H1 2016 16 Diabetic Peripheral Neuropathy - Pipeline by Commence Bio, Inc., H1 2016 17 Diabetic Peripheral Neuropathy - Pipeline by Nuvo Research Inc., H1 2016 18 Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H1 2016 19 Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics S.A., H1 2016 20 Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 48 Diabetic Peripheral Neuropathy - Dormant Projects, H1 2016 52 Diabetic Peripheral Neuropathy - Discontinued Products, H1 2016 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.